Oncology drug development company Celsion Corporation (NASDAQ: CLSN) Thursday reported a narrower net loss for the second quarter of 2019, reflecting a decrease in operating expenses.
The company reported a net loss of $5.9 million or $0.29 per share for the June quarter, marking an improvement from a loss of $8.2 million or $0.46 per share reported a year earlier. The bottom-line benefitted from a 30% decline in operating expenses to $5.7 million.
At $3.6 million, research and development expenses were down 22% from the year-ago period. Also, there was a modest decline in the clinical development costs for the phase-III OPTIMA Study as enrollment in the key clinical trial ended last year.
Also read: Canopy Growth stock falls on wider-than-expected Q1 loss
Celsion recorded revenues of $125,000 for the quarter, solely comprising licensing revenue, which is in line with the prior-year quarter.
“With a clear focus on shareholder value, Celsion continues to execute its business plan for our ongoing clinical development programs with ThermoDox and GEN-1. We are exceptionally well positioned on the fundamentals with a strong balance sheet that is expected to fund our clinical programs through transformative milestones over the next 18 months,” said CEO Michael Tardugno.
At the end of the quarter, Celsion had cash, investment securities and interest receivable of $21.8 million. The company intends to fund its future operations, up to the first quarter of 2021, using the available cash and benefits from the New Jersey NOL program.
Celsion shares closed the last trading session notably higher. The stock has lost about 33% in the past twelve months and is currently trading below $2.
Most Popular
T Earnings: All you need to know about AT&T’s Q1 2024 earnings results
AT&T Inc. (NYSE: T) reported its first quarter 2024 earnings results today. Revenues dipped slightly to $30 billion from $30.1 billion in the year-ago quarter. Net income attributable to common
V Earnings: All you need to know about Visa’s Q2 2024 earnings results
Visa (NYSE: V) reported its second quarter 2024 earnings results today. Net revenue increased 10% year-over-year to $8.8 billion. GAAP net income grew 10% to $4.7 billion and EPS rose
Tesla (TSLA) reports lower Q1 revenue and earnings; results miss estimates
Electric vehicle giant Tesla Inc. (NASDAQ: TSLA) Tuesday reported lower revenues and earnings, on an adjusted basis, for the first quarter of 2024. The Austin-based carmaker said its first-quarter revenues